Tech Company Financing Transactions
Beta Cat Pharmaceuticals Funding Round
On 6/28/2018, Beta Cat Pharmaceuticals secured $2.6 million in funding from private investors.
Transaction Overview
Company Name
Announced On
6/28/2018
Transaction Type
Venture Equity
Amount
$2,600,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed. 3 investors participated in the offering. The amount may include options, warrants or other securities. Contact technology company for investment details, if applicable. Not an offer or solicitation for the sale of securities or debt. SEC regulatory filing.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2450 Holcombe Blvd. J606
Houston, TX 77021
USA
Houston, TX 77021
USA
Phone
Website
Email Address
Overview
Central pathway for cell growth, development and differentiation of normal stem cells. Frequently activated in cancers Activating mutations in multiple pathway components Essential survival signal in cancer stem cells Limited toxicities predicted from inhibition of nuclear beta catenin in adult tissues.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Rahul Aras
Chief Financial Officer
Scott Jordan
Chief Medical Officer
Casey Cunningham
Chief Scientific Officer
Steve Horrigan
Controller
Uma Bhatt
VP - Bus. Development
Jeffrey Larson
VP - Operations
Rose Hernandez
Browse more venture capital transactions:
Prev: 6/28/2018: SimpleNexus venture capital transaction
Next: 6/28/2018: FirstVet venture capital transaction
Share this article
About Our VC Transactions Data
We report on tech company VC transactions. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs